Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Blackburn, Rachel C ^a   Parke, Claire L ^a   Sharma, Pawana ^a   McCullough, Keith ^a   Black, Corri ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; EPROSARTAN; FOSINOPRIL; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ADULT DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 70349154621     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007751     Document Type: Review

References (26)

1. Astor BC, Eustace JA, Powe NR, Klag MJ, Sadler JH, Fink NE, et al.The timing of nephrologist referral and artiovenous access use: the CHOICE study. American Journal of Kidney Diseases 2001;38(3):494-501. [MEDLINE: 11532680]
2. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR - Morbidity & Mortality Weekly Report 2007;56(8):161-165 [MEDLINE: 17332726]
3. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, et al.Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. Journal of the American Society of Nephrology 2005;16(1):180-188 [MEDLINE: 15563563]
4. Dahlof B, Sever PS, Poulter NR, Wedel H, Caulfield M, et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised control trial. Lancet 2005;366 (9489):895-906. [MEDLINE: 16154016] (Pubitemid 41265663)
5. Daly C. Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation 2007;22(Suppl 9):ix19-25. [MEDLINE: 17998227]
6. Dogan E, Erkoc R, Sayarlioglu H, Durmus A, Topal C. Effects of late referral to a nephrologist in patients with chronic renal failure. Nephrology 2005;10(5):516-519 [MEDLINE: 16221105] (Pubitemid 41727279)
7. Drey N, Roderick P, Muliee M, Rogerson M. A population-base study of the incidence and outcomes of diagnosed chronic kidney disease. American Journal of Kidney Diseases 2003;42(4):677-684 [MEDLINE: 14520617] (Pubitemid 37187367)
8. Giatras I, Lau J, Levey AS. The effect of angiotensin converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomised trials. Annals of InternalMedicine 1997;127(5):337-345 [MEDLINE: 9273824] (Pubitemid 27362741)
9. Hallan SI, Dahl K, OienCM,GrootendorstDC, Aasberg A,Holmen J, et al.Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006;333(7577):1047. [MEDLINE: 17062598] (Pubitemid 44807817)
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560 [MEDLINE: 12958120]
11. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008. Available from www.cochranehandbook. org.
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine 2000;342(3):145-153 [MEDLINE: 10639539] (Pubitemid 30051645)
13. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al.Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by theMDRDequationmodified by a Japanese coefficient. Clinical&ExperimentalNephrology 2007;11(2):156-163 [MEDLINE: 17593516] (Pubitemid 47012510)
14. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al.Progression of chronic kidney disease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition. Annals of Internal Medicine 2003;139(4):244-253 [MEDLINE: 12965979] (Pubitemid 38129085)
15. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. American Journal of Kidney Diseases 2004;43(5):825-835 [MEDLINE: 15112173] (Pubitemid 38529620)
16. Khan S, Amedia CA Jr. Economic burden of chronic kidney disease. Journal of Evaluation in Clinical Practice 2007;14(3):422-434 [MEDLINE: 18373575]
17. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al.The timing of specialist evaluation in chronic kidney disease and mortality. Annals of Internal Medicine 2002;137(6):479-486 [MEDLINE: 12230348] (Pubitemid 35024618)
18. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. American Journal of Kidney Diseases 2000;35(4):695-707. [MEDLINE: 10739792]
19. Kumar PJ, Clark ML, editors. Kumar & Clark clinical medicine. 5th Edition. Edinburgh: W.B. Saunders, 2002:591-2, 825.
20. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org.
21. Levey AS, Coresh J, Balk M, Kausz AT, Levin A, Steffes MW, et al.National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine 2003;139(2):137-147 [MEDLINE: 12859163] (Pubitemid 38129105)
22. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed February 2009).
23. MetcalfeW.How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology Dialysis Transplantation 2007;22 (9):ix26-30. [MEDLINE: 17998229]
24. Willis NS,Mitchell R,HigginsGY,Webster AC,Craig JC. Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs) 2009, Issue 1. Art. No.: RENAL (accessed January 2009).
25. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. Journal of the American Society of Nephrology 2006;17(11):2985-2991 [MEDLINE: 17035613] (Pubitemid 44707758)
26. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006257] * Indicates the major publication for the study (Pubitemid 46841144)